Alkermes PLC (NAS:ALKS)
$ 29.65 0.15 (0.51%) Market Cap: 4.80 Bil Enterprise Value: 4.25 Bil PE Ratio: 15.21 PB Ratio: 3.71 GF Score: 69/100

Alkermes Plc at Cowen HealthCare Conference Transcript

Mar 02, 2020 / 08:30PM GMT
Release Date Price: $19.74 (+1.92%)
Chris Shibutani
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Let's get underway. Good afternoon. My name is Chris Shibutani, I'm a member of the Cowen biotech equity research team. We are very pleased once again to have Alkermes join us for our 40th annual conference.

I think it's very clear that there are certain pursuits, in particular, addiction, CNS disease, psychiatric disease, immuno-oncology, where all of us recognize the incredible difficulty that's associated with this, whether it's science, whether it's even just trying to understand what is the definition of success. There's no simple LDL cholesterol number that they're trying to hit. There are objectives. They're constantly being in pursuit. They're constantly changing as we learn more and requires a degree of adaptability. In order to be able to manage a business with that, it takes some discipline and some strategy. This is a year where the stock is attractively valued at a point where the company is redefining their strategy as they're continually defining and redefining what the endpoints and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot